New stock news | Weikang Probiotics submits application for listing on the Hong Kong Stock Exchange main board, mainly engaged in the research, production, and sales of probiotic strains.

According to the disclosure from the Hong Kong Stock Exchange on April 29th, Wei Kang Probiotics (Suzhou) Co., Ltd. (referred to as Wei Kang Probiotics) has submitted its listing application to the Hong Kong Stock Exchange Main Board, with Guotai Haitong as the sole sponsor. Company Overview The prospectus shows that Wei Kang Probiotics is a leading global biomanufacturing company, primarily engaged in the research, development, production, and sale of probiotic strains. According to Frost & Sullivan data, the company's probiotic original powder production volume ranked third globally in 2025, and first in Asia. The company is committed to providing high-activity, high-stability, and functional probiotic powder, probiotic preparations, and dairy fermentation agents for human health (functional foods and dietary supplements), dairy, and agriculture companies through independently developed probiotic strains and supporting production processes. Currently, the company has independently developed and achieved industrialization of core strains such as WecLac including BLa80 animal bifidobacteria, LRa05 lactobacillus rhamnosus, BC99 Bacillus coagulans, BL21 Escherichia coli, and Akk11 mucinophilic Akkermansia muciniphila. The strain-specific functional characteristics of the core probiotic strains in various applications have been verified in human research and other clinical validation activities. The company is one of the few globally that simultaneously develop functional probiotic strains and have high-standard industrial production capabilities. As of April 20, 2026, the company has established intelligent production base in Suzhou, Jiangsu Province and Luohe, Henan Province, China, with an annual production capacity of 700 tons of human health food and dairy application probiotic original powder, over 5,000 tons of human health food probiotic preparations, and 1,000 tons of beneficial microbiology original powder for agriculture. The company's probiotic powder and preparation products mainly include products for human health, dairy, agriculture, and other sectors. The revenue breakdown is as shown in the following chart. The company's products have been sold to over 60 countries and territories, covering mainstream markets such as China, North America, Europe, Australia, and have established four overseas offices, gradually establishing a broad and responsive international marketing and service network. Financial Information Revenue In the fiscal years of 2023, 2024, and 2025, the company recorded revenues of approximately 496 million, 544 million, and 701 million RMB respectively. Profit In the fiscal years of 2023, 2024, and 2025, the company recorded annual profits of approximately 25.42 million, 79.614 million, and 65.21 million RMB respectively. Gross Profit In the fiscal years of 2023, 2024, and 2025, the company recorded gross profits of approximately 2.47 billion, 2.65 billion, and 3.33 billion RMB respectively. Industry Overview The global probiotics market has experienced strong growth in recent years. The total market size increased from 587 billion USD in 2020 to 867 billion USD in 2025, with a CAGR of 8.1% from 2020 to 2025. The market is expected to further expand to 1.511 trillion USD in 2030, with a CAGR of 11.8% from 2025 to 2030, and is projected to reach 2.796 trillion USD in 2035, reflecting a CAGR of 13.1% from 2030 to 2035. The global probiotic original powder market size increased from 23.23 billion USD in 2020 to 32.64 billion USD in 2025, with a CAGR of 7.0% from 2020 to 2025. The market size is expected to further expand to 48.21 billion USD in 2030, with a CAGR of 8.1% from 2025 to 2030, and reach 81.54 billion USD in 2035, reflecting a CAGR of 11.1% from 2030 to 2035. The market size of probiotic original powder in China increased from 316 million USD in 2020 to 483 million USD in 2025, with a CAGR of 8.8% from 2020 to 2025. The market is expected to further expand to 794 million USD in 2030, with a CAGR of 10.5% from 2025 to 2030, and reach 1.401 billion USD in 2035, reflecting a CAGR of 12.0% from 2030 to 2035. The market size of probiotic original powder in North America increased to 717 million USD in 2025, with a CAGR of 7.3% from 2020 to 2025. The market size is expected to further expand to 1.085 billion USD in 2030, with a CAGR of 8.6% from 2025 to 2030, and reach 1.964 trillion USD in 2035, reflecting a CAGR of 12.6% from 2030 to 2035. The market size of probiotic original powder in Europe increased from 551 million USD in 2020 to 779 million USD in 2025, with a CAGR of 7.2% from 2020 to 2025. The market size is expected to further expand to 1.162 billion USD in 2030, with a CAGR of 8.3% from 2025 to 2030, and reach 2.004 billion USD in 2035, reflecting a CAGR of 11.5% from 2030 to 2035. The global probiotic original powder market shows a clear regional growth trend. In terms of regional share, Europe had the largest share in 2025 at 23.9%, followed by North America (22.0%) and China (14.8%). By 2030, these proportions are expected to change to 24.1%, 22.5%, and 16.5%, respectively. Probiotic original powder is a critical material for downstream production in the entire cycle (including probiotic powder, probiotic preparations, and probiotic end products). As shown in the table below, the company's probiotic original powder production volume ranked third globally in 2025 and first in Asia, with a total output of 328 tons. Board of Directors and Executive Information The company's board of directors will consist of 7 directors, including 3 executive directors, 1 non-executive director, and 3 independent non-executive directors. Directors serve a term of 3 years and are eligible for re-election. Equity Structure As of April 20, 2026, Dr. Fang (the founder, chairman of the board, chief scientist, and executive director of the company) controls approximately 33.60% of the voting rights of the company's issued shares, including 18.03% directly held by Dr. Fang and 15.57% indirectly held through controlled entities. Intermediary Team Exclusive Sponsor: HAITONG INT'L CAPITAL LIMITED Company Legal Advisors: Smithfield LLP for Hong Kong and U.S. law; TransChina Law Firm for Chinese law Exclusive Sponsor Legal Advisors: JiaYuan Law Firm for Hong Kong and U.S. law; JiaYuan Law Firm for Chinese law Auditor and Reporting Accountant: Deloitte Touche Tohmatsu Limited Industry Consultant: Frost & Sullivan (Beijing) Consulting Co., Ltd., Shanghai Branch Compliance Advisor: Dymon Asia Capital Limited